Indomo Launches Out of Stealth with $25M to Bring Instant, At-Home Acne Injections to Consumers

Imagine this: just as one breakout finally starts to heal, another inflamed pimple surfaces – red, swollen, and impossible to ignore. They always seem to arrive at the worst times, whether before a client meeting, a first date, or school picture day. For people living with inflammatory acne, this cycle is constant, and with dermatology offices booked months out, patients are left to manage the swelling, pain, and scarring on their own.

Enter Indomo: the therapeutics company developing at-home prescription dermatology treatments. Today, Indomo emerged from stealth with $25 million in funding and introduced the ClearPen™, an investigational at-home injectable acne therapy in development for the treatment of inflammatory acne lesions. (ClearPen has not been approved or cleared by the U.S. FDA; its safety and efficacy have not been established.)

Acne is the most common skin condition in the U.S., affecting 50 million Americans annually. Almost half of acne sufferers (20 million) struggle with inflammatory acne, yet only 1 million people are regularly receiving corticosteroid injections to treat their lesions. The root cause of this issue is accessibility. With only 12,000 dermatologists in the U.S., there is only one dermatologist for every 28,000 Americans. By the time patients finally get seen, the lesion that mattered has often already scarred, not just leaving a mark on their skin, but on their confidence, influencing how they show up at school, at work, or in everyday life. Indomo aims to change that by pursuing an at-home approach intended to empower patients with timely access to care.

Today’s modern healthcare system bridges traditional in-person care with virtual care and new technologies in order to expand access for patients. From the first insulin injections to modern GLP-1s and fertility treatments, self-injection devices have made it possible to safely bring clinical care into the home. Now, Indomo is building off this scientific progress with its own intradermal self-injection technology.

“ClearPen will be the first big innovation in acne care since Accutane,” said Jack Abraham, CEO of Atomic; co-founder of Indomo and co-founder of Hims & Hers. “For too long, people have had to choose between ineffective surface treatments or waiting weeks for a dermatologist. ClearPen will provide patients instant access to a corticosteroid microneedle injection right in their bathroom cabinet.”

Built by a team with deep expertise in medical devices, consumer health, and skincare, Indomo is developing a platform that pairs a proprietary self-injection device and microneedle with a modernized formulation of triamcinolone acetonide to enable consistent dosing for at-home administration. Intralesional injections of triamcinolone acetonide, a corticosteroid backed by 50+ years of clinical use and a strong safety profile, are recommended as one of the first-line treatments for acne by the American Academy of Dermatology.

“For over 50 years, dermatologists have relied on corticosteroid injections to treat inflammatory acne, yet access to this treatment has remained limited to the doctor’s office. At Indomo, we are working to change that. By pairing a trusted therapeutic with our investigational microneedle delivery device, we’re hoping to empower people to treat breakouts the moment they appear,” said Rick Bente, CEO of Indomo.

Backed with $25 million in total funding from leading investors like Atomic, Foresite Capital, and Polaris Partners, Indomo is using this capital to support its Phase 2 clinical trials and the development of its device platform. Long-term, the company’s goal is to leverage its ClearPen technology to address other skin conditions historically limited to in-office care, such as keloids and hidradenitis suppurativa.

“We look for teams that marry scientific rigor with practical impact,” said Hyung Chun, Partner at Foresite Capital. “Indomo applies proven dermatology science in an accessible, patient-friendly format—with an emphasis on precision and patient safety during development. That combination is rare, and it’s why we believe ClearPen has the potential to meaningfully change how people manage inflammatory acne.”

Indomo’s advisors include:

• Brent Saunders, CEO, Bausch + Lomb; former CEO, Allergan
• Patricia Walker, MD, PhD, Former Chief Scientific Officer, Allergan Medical Aesthetics; former President and CSO, Brickell Biotech; former Chief Medical Officer, Kythera Biopharmaceuticals
• Arash Mostaghimi, MD, Vice Chair of Clinical Trials and Innovation, Brigham & Women’s Hospital Dept. of Dermatology; Associate Professor, Harvard
• Justin Ko, MD, Chief of Medical Dermatology and Professor, Stanford

To learn more about Indomo and their Phase 2 clinical trials, head here.

Disclaimer: The Indomo ClearPen has not yet been approved or cleared by the U.S. Food and Drug Administration and is considered investigational; preparations are underway for Phase 2 clinical trials.

About Indomo:
Indomo is reimagining clinical dermatology with trusted science and precision technology, bringing medical-grade care into the home. A clinical-stage therapeutics company, Indomo pairs proven medicines with novel delivery systems to create fast-acting, self-administered treatments for inflammatory skin conditions. Its debut product, the ClearPen, combines an established, trusted therapeutic with a novel microneedle device for at-home acne treatment. Indomo is backed by leading investors including Atomic, Foresite Capital, Polaris Partners, Storyhouse Ventures, Myelin, Gaingels, and Form Life. Founded by leaders from Hims & Hers, Medtronic, and Starface, Indomo brings together deep expertise in telehealth, medical devices, and consumer skincare.

Contact Information

Brook Fowler

Manager

VSC for Indomo

Contact via E-mail